METTL3 promotes inflammation and cell apoptosis in a pediatric pneumonia model by regulating EZH2

Ying Yang1, Xiaoqing Yang2, Yi Wu3

  • 1Department of Pediatrics, Women and Children's Hospital, School of Medicine, Xiamen University, Xiamen, Fujian China.

Abstract

Insights

Methyltransferase-like 3 (METTL3) promotes pediatric pneumonia by increasing inflammation and cell apoptosis. Downregulating METTL3 inhibits these effects by regulating EZH2 and the JAK2/STAT3 pathway.

Area of Science:

  • Molecular Biology
  • Immunology
  • Pediatrics

Background:

  • The molecular mechanisms underlying pediatric pneumonia remain largely unclear.
  • Methyltransferase-like 3 (METTL3) is implicated in inflammatory diseases, but its specific role in pediatric pneumonia requires elucidation.

Purpose of the Study:

  • To investigate the molecular mechanism of METTL3 in pediatric pneumonia, focusing on inflammation and cell apoptosis.
  • To explore the role of METTL3 in regulating the JAK2/STAT3 signaling pathway and its interaction with EZH2.

Main Methods:

  • Quantitative real-time PCR and Western blot to assess METTL3 and EZH2 expression in patient samples and cell models.
  • ELISA and MTT assays to evaluate inflammatory responses, cell viability, and apoptosis in LPS-treated cells with altered METTL3 levels.
  • Analysis of JAK2/STAT3 pathway activation following METTL3 modulation.

Main Results:

  • METTL3 and EZH2 were found to be highly expressed in pediatric pneumonia patients and cell models.
  • Downregulation of METTL3 significantly inhibited lipopolysaccharide (LPS)-induced inflammation and cell apoptosis.
  • METTL3 was demonstrated to regulate the JAK2/STAT3 signaling pathway via EZH2, thereby influencing inflammation and apoptosis.

Conclusions:

  • METTL3 plays a crucial role in promoting inflammation and cell apoptosis in pediatric pneumonia.
  • Targeting METTL3, potentially through its regulation of EZH2, offers a promising therapeutic strategy for pediatric pneumonia.